- Long-term collaboration to harness new scientific discoveries in areas of high unmet medical need such as cardiometabolic disease, cancer immunology and new therapeutic approaches such as regenerative medicine and gene therapy
- New partnership with one of the worldwide leading life science research institutions aims to expand portfolio of R&D projects with first in class and breakthrough potential
INGELHEIM, Germany & BEIJING, China--(BUSINESS WIRE)--Boehringer Ingelheim and Peking University (PKU) today announced an ambitious strategic partnership with the aim of jointly advancing early science innovation across a range of areas of high medical need.
The partnership will implement a multifaceted collaboration model that nimbly and flexibly caters for the specific needs of the involved research groups. It will comprise project based research, a joint post-doctorate fellowship program and a number of Boehringer Ingelheim endowed investigators. The partnership aims to strengthen Boehringer Ingelheim’s portfolio of early and unique pipeline projects supporting the company’s aspiration to be at the forefront of science and technology and deliver more first in class medicines with breakthrough potential. It takes Boehringer Ingelheim’s research and development efforts in Asia to the next level.
Media + PR
Phone: +49 6132 – 77 90815
Fax: +49 6132 – 77 6601